Primary Prevention With Statin and Incidence of Recurrent MI and Cardiogenic Shock in Post-ACS Patients

Overview

This study aims to evaluate the effect of statin for primary prevention, towards lowering the incidence of recurrent myocardial infarction, cardiogenic shock and mortality in ACS patients.

Full Title of Study: “Primary Prevention With Statin and Incidence of Recurrent Myocardial Infarction and Cardiogenic Shock in Post-Acute Coronary Syndrome Patients”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: June 30, 2018

Detailed Description

Adult patients (≥ 18 years of age) with acute coronary syndrome which are diagnosed under ICD-10 coding of I24.9 were included in this study. The inclusion criteria are patients with primary diagnosis of I24.9 and with a complete record of prior medical and treatment history, electrocardiographic findings, cardiac marker results and outcomes. Participants were grouped into 2 groups – statin and non-statin based on prior history of statin use prior to ACS. Diagnosis of ACS was made based on clinical, electrocardiographic and cardiac marker findings found in the medical record. Data such as age, sex, ethnic, education, prior medical and treatment history, electrocardiographic and cardiac enzyme results as well as outcomes were collected from the patients' medical records. Outcomes of interest were defined as either recurrent myocardial infarction, cardiogenic shock, mortality or combinations of them as diagnosed in the medical records. GRACE and TIMI Scores are calculated to predict in hospital and future mortality rates.

Interventions

  • Drug: Statin
    • Prescribed with statins for primary prevention

Arms, Groups and Cohorts

  • Statin
    • History of statin use for primary prevention
  • Non-Statin
    • No documented history of statin use prior to Acute Coronary Syndrome

Clinical Trial Outcome Measures

Primary Measures

  • Recurrent Myocardial Infarction
    • Time Frame: Through study completion, an average of 1 year
    • Clinical Diagnosis of Recurrent Myocardial Infarction reported in medical records
  • Cardiogenic Shock
    • Time Frame: Through study completion, an average of 1 year
    • Clinical Diagnosis of Cardiogenic Shock reported in medical records
  • Mortality
    • Time Frame: Through study completion, an average of 1 year
    • Patient death reported in medical records

Participating in This Clinical Trial

Inclusion Criteria

  • Clinical diagnosis of Acute Coronary Syndrome – Presence of detail on statin prescription history Exclusion Criteria:

  • Unavailability of electrocardiographic findings, cardiac marker results, GRACE and TIMI score parameters – Incomplete records of prior medical and treatment history

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Tarumanagara University
  • Collaborator
    • Cengkareng General Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Angela Felicia Sunjaya, Principal Investigator – Tarumanagara University
  • Overall Official(s)
    • Angela F Sunjaya, Study Chair, Tarumanagara University
    • Anthony P Sunjaya, Principal Investigator, Tarumanagara University
    • Andria Priyana, MD, FIHA, Principal Investigator, Department of Cardiology, Faculty of Medicine, Tarumanagara University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.